Voyager Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$135M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Voyager Therapeutics's estimated annual revenue is currently $15.9M per year.(i)
  • Voyager Therapeutics received $75.0M in venture funding in November 2017.
  • Voyager Therapeutics's estimated revenue per employee is $114,245
  • Voyager Therapeutics's total funding is $135M.
  • Voyager Therapeutics's current valuation is $108.2M. (January 2022)

Employee Data

  • Voyager Therapeutics has 139 Employees.(i)
  • Voyager Therapeutics grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.8M73-39%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$3.1M2663%N/AN/A
#4
$29.6M12518%$351MN/A
#5
$15.8M84-18%$312.8MN/A
#6
$235M269-43%$340.9MN/A
#7
$2.2M284%N/AN/A
#8
$6M3413%$176.5MN/A
#9
N/A929%N/AN/A
#10
$1.8M249%N/AN/A
Add Company

Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson's disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Alzheimer's Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data. Contact: Voyager Therapeutics 75 Sidney St. Cambridge, MA 02139 info@voyagertherapeutics.com 857-259-5340

keywords:Biotechnology,Healthcare,Pharmaceuticals

$135M

Total Funding

139

Number of Employees

$15.9M

Revenue (est)

15%

Employee Growth %

$108.2M

Valuation

N/A

Accelerator

Voyager Therapeutics News

2022-04-19 - Voyager Therapeutics (NASDAQ:VYGR) Upgraded to “Buy” at StockNews.com

Read Voyager Therapeutics (NASDAQ:VYGR) Upgraded to “Buy” at StockNews.com at Defense World.

2022-04-17 - Voyager Therapeutics Down 34%; Two Board Members Won't Seek Re-Election

By Josh Beckerman. Voyager Therapeutics Inc. shares were recently down 33% to $6.75 and were briefly paused due to volatility more than an...

2022-04-17 - Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last?

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate...

2021-10-06 - Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance

With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the protein shells that envelope a gene therapy and deliver it into a target cell. That strategy is starti ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$38.6M1393%N/A
#2
$7.5M139N/AN/A
#3
$7.5M139N/AN/A
#4
$33.5M1408%N/A
#5
$37.7M140N/AN/A

Voyager Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-02-13$45.0MAThird Rock VenturesArticle
2015-02-12$30.0MUndisclosedGenzymeArticle
2015-04-14$60.0MBBrookside CapitalArticle
2017-11-08$75.0MUndisclosedMorgan StanleyArticle

Voyager Therapeutics Executives


NameTitle
Michelle SmithChief Human Resources Officer
Alfred SandrockChief Executive Officer
Peter PfreundschuhChief Financial Officer
Todd CarterChief Scientific Officer
Allen NunnallyChief Business Officer
Scott TownsendChief Corporate Counsel and Senior Vice President of Legal Affairs
Rachael DiMesticoExecutive Assistant to Chief Medical Officer and SVP of Neuroscience
Michelle Quinn SmithChief Human Resources Officer
Steven PaulCEO and Chairman of the Board
Robin SwartzChief Operating Officer
Andre TurennePresident & CEO
Glenn PierceInterim Chief Scientific Officer
Trista MorrisonSVP of Corporate Affairs
Chad HollandVice President, Program, Portfolio & Alliance Management
Christina Gamba-VitaloVice President Toxicology and DMPK
Holger PatzkeVice President, Neuroscience and Head of Translational Biology
Scott TownsendChief Corporate Counsel and Senior Vice President of Legal Affairs
Charlie HarperVice President CMC, Ext Manufacturing and Supply
Jennifer HuntSenior Vice President, Development Operations and Regulatory Affairs
Rachael DiMesticoExecutive Assistant to Chief Medical Officer and SVP of Neuroscience
Petra SansomVice President, Alliance Management
Brandi SimpsonVice President, Business and Corporate Development
Julie BurekVice President, Finance
Kelly BalesSVP Neuroscience
Andre TurennePresident & CEO
Juliana MuscatVice President of Quality
Claire SampsonVP Global Regulatory Affairs
Jay HouVice President, Vector Engineering
Holger PatzkeVice President, Neuroscience and Head of Translational Biology